The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast Cancer
Open accessAbstract
Purpose: Five years of adjuvant tamoxifen therapy for estrogen receptor (ER) –positive breast cancer is more effective than 2 years of use. However, information on tamoxifen discontinuation is scanty. We sought to identify predictors of tamoxifen discontinuation among older women with breast cancer. Patients and Methods: Within six health care delivery systems, we identified women ≥ 65 years old diagnosed with stage I to IIB ER-positive or indeterminant breast cancer between 1990 and 1994 who had filled a prescription for adjuvant tamoxifen. We observed them for 5 years after initial tamoxifen prescription. We used automated pharmacy records to validate tamoxifen prescription information abstracted from medical records. The primary end point was tamoxifen discontinuation, operationalized as ever discontinuing tamoxifen during 5 years of follow-up. We used Cox proportional hazards to identify predictors of tamoxifen discontinuation. Results: Of 961 women who were prescribed tamoxifen, 49% discontinued tamoxifen before the completion of 5 years. Discontinuers were more likely to be aged 75 to less than 80 years (v < 70 years; hazard ratio [HR] = 1.41; 95% CI, 1.06 to 1.87), be aged ≥ 80 years (HR = 2.02; 95% CI, 1.53 to 2.66), have an increase in Charlson Comorbidity Index at 3 years from diagnosis (HR = 1.52; 95% CI, 1.18 to 1.95), have an increase in the number of cardiopulmonary comorbidities at 3 years (HR = 1.75; 95% CI, 1.34 to 2.28), have indeterminant ER status (v ER-positive status; HR = 1.36; 95% CI, 1.00 to 1.85), and have received breast-conserving surgery (BCS) without radiotherapy (v mastectomy; HR = 1.62; 95% CI, 1.18 to 2.22). Conclusion: Attention to nonadherence among older women at risk of discontinuation, particularly those receiving BCS without radiotherapy, might improve breast cancer outcomes for these women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
The assessment of refill compliance using pharmacy records: Methods, validity, and applications
Steiner, J. F., & Prochazka, A. V. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00268-5 · Cited by 1,193
Hughes, K. S., Schnaper, L. A., Berry, D., Cirrincione, C., McCormick, B., Shank, B., Wheeler, J., Champion, L. A., Smith, T. J., Smith, B. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040587 · Cited by 1,078
Potential Pitfalls of Disease-Specific Guidelines for Patients with Multiple Conditions
Tinetti, M. E., Bogardus, S. T., & Agostini, J. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmsb042458 · Cited by 927
Powles, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05071-5 · Cited by 902
Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 861
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Wood, W. C., Senn, H.-J., Glick, J. H., & Gelber, R. D. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1441 · Cited by 689
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
Chan, K. A., Andrade, S. E., Boles, M., Buist, D. S., Chase, G. A., Donahue, J. G., Goodman, M. J., Gurwitz, J. H., LaCroix, A. Z., & Platt, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02400-4 · Cited by 391
Self-citationMeeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., & Senn, H.-J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1601 · Cited by 380
Validation of pharmacy records in drug exposure assessment
Lau, H. S., de Boer, A., Beuning, K. S., & Porsius, A. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00040-1 · Cited by 370
Balkrishnan, R., Rajagopalan, R., Camacho, F. T., Huston, S. A., Murray, F. T., & Anderson, R. T. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80347-8 · Cited by 350
Tamoxifen for Prevention of Breast Cancer
Cersosimo, R. J. (2003) · Annals of Pharmacotherapy · doi:10.1177/106002800303700219 · Cited by 343
Ellis, J. J., Erickson, S. R., Stevenson, J. G., Bernstein, S. J., Stiles, R. A., & Fendrick, A. M. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30516.x · Cited by 323
Adherence to tamoxifen over the five-year course
Lash, T. L., Fox, M. P., Westrup, J. L., Fink, A. K., & Silliman, R. A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9193-0 · Cited by 320
Self-citationAdjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 300
Self-citationMalin, J. L., Schneider, E. C., Epstein, A. M., Adams, J., Emanuel, E. J., & Kahn, K. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3365 · Cited by 293
Fink, A. K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.064 · Cited by 281
Self-citationEarly discontinuation of tamoxifen: A Lesson for oncologists
Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy, M. J. (2007) · Cancer · doi:10.1002/cncr.22485 · Cited by 279
Monane, M. (1997) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00056-3 · Cited by 276
Monane, M., Bohn, R. L., Gurwitz, J. H., Glynn, R. J., Levin, R., & Avorn, J. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.12.1805 · Cited by 253
Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007) · Medical Care · doi:10.1097/01.mlr.0000257193.10760.7f · Cited by 245
Adherence beliefs among breast cancer patients taking tamoxifen
Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. (2005) · Patient Education and Counseling · doi:10.1016/j.pec.2004.10.005 · Cited by 245
Psychological and cognitive function: Predictors of adherence with cholesterol lowering treatment
Stilley, C. S., Sereika, S., Muldoon, M. F., Ryan, C. M., & Dunbar-Jacob, J. (2004) · Annals of Behavioral Medicine · doi:10.1207/s15324796abm2702_6 · Cited by 223
Hormone Therapy Prescribing Patterns in the United States
Buist, D. S. M., Newton, K. M., Miglioretti, D. L., Beverly, K., Connelly, M. T., Andrade, S., Hartsfield, C. L., Wei, F., Chan, K. A., & Kessler, L. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000143826.38439.af · Cited by 213
Self-citationBreast Cancer Treatment of Older Women in Integrated Health Care Settings
Enger, S. M., Thwin, S. S., Buist, D. S. M., Field, T., Frost, F., Geiger, A. M., Lash, T. L., Prout, M., Yood, M. U., Wei, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3065 · Cited by 171
Self-citationNCCN Task Force Report: Adjuvant Therapy for Breast Cancer
Carlson, R. W., Brown, E., Burstein, H. J., Gradishar, W. J., Hudis, C. A., Loprinzi, C. L., Mamounas, E. P., Perez, E. A., Pritchard, K. I., Ravdin, P. M., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2001 · Cited by 140
Balkrishnan, R., Bhosle, M. J., CAMACHO, F. T., & Anderson, R. T. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00352-6 · Cited by 84
Advanced age and adjuvant tamoxifen prescription in early‐stage breast carcinoma patients
Blackman, S. B., Lash, T. L., Fink, A. K., Ganz, P. A., & Silliman, R. A. (2002) · Cancer · doi:10.1002/cncr.10985 · Cited by 25
Self-citation
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.-Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 828
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
Metadata
- Authors
- Owusu, C., Buist, D. S. M., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., Quinn, V. P., Frost, F., Prout, M., Yood, M. U., Wei, F., & Silliman, R. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-02-01
- Volume
- 26
- Issue
- 4
- Pages
- 549-555
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2169902698
- Cited by
- 304
- References
- 33
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.